
Evommune Inc (EVMN) Stock Forecast & Price Target
Evommune Inc (EVMN) Analyst Ratings
Bulls say
Evommune is expected to have a strong, well-differentiated profile in the chronic urticaria market with the potential for oral convenience and a broad mechanism of action. Additionally, their entry into the migraine market with EVO301 adds a valuable, under-the-radar element to the company's story. Finally, Evommune has a credible potential for multi-asset franchise in the dermatology space, and their current progress and pipeline make them an attractive investment opportunity for potential buyers.
Bears say
Evommune is a clinical-stage biotechnology company with a focus on developing therapies for chronic inflammatory diseases such as chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). As a financial analyst, I have a negative outlook on the company's stock due to several fundamental reasons. These include the company's limited pipeline, high-risk clinical programs, possible delays in regulatory approval, competition from established biotech companies, and lack of revenue.
This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.
Evommune Inc (EVMN) Analyst Forecast & Price Prediction
Start investing in Evommune Inc (EVMN)
Order type
Buy in
Order amount
Est. shares
0 shares